Alloimmunization and HDFN Day

Show Support for the Allo Hope Foundation

Get involved with Alloimmunization and HDFN Day by making a difference in the life of a family who is impacted by this medical disease. Whether making a donation or volunteering for this non-profit organization, get involved and show support for mothers with alloimmunization by helping to provide care and preventative treatment for people in underserved communities in the United States and other countries around the world. Alloimmunization and HDFN Day FAQsWhat is maternal red blood cell alloimmunization and how does it lead to HDFN? Maternal red blood cell alloimmunization occurs when a pregnant person is exposed to fetal red blood cell antigens that are different from their own, usually through fetomaternal hemorrhage in pregnancy, delivery, miscarriage, invasive procedures, or prior transfusion. The immune system may form IgG antibodies against these “foreign” antigens. In a subsequent or ongoing pregnancy with an antigen‑positive fetus, these antibodies can cross the placenta, attach to fetal red blood cells, and trigger their destruction. This process can cause hemolytic disease of the fetus and newborn (HDFN), leading to fetal anemia, hydrops fetalis, heart failure, or stillbirth if not recognized and treated.  Is HDFN only caused by RhD incompatibility, or can other blood group antibodies be involved? HDFN is often associated with RhD incompatibility, but many other red blood cell antibodies can cause the disease. Clinically important non‑RhD antibodies include anti‑K (Kell), anti‑c, anti‑E, anti‑C, anti‑G, and certain Duffy, Kidd, and MNS antibodies. In high‑income countries, widespread use of Rh immune globulin has reduced RhD‑related HDFN, so a growing proportion of severe cases are now linked to non‑RhD antibodies such as Kell. These antibodies can be detected on routine antenatal antibody screening, and some, like Kell, may cause severe fetal anemia even at relatively low titers.  How is an at‑risk pregnancy monitored when a parent is alloimmunized? When clinically significant antibodies are identified, care teams typically monitor antibody titers at regular intervals and assess whether the fetus carries the corresponding antigen. If titers rise above a critical threshold or there is a history of a previously affected pregnancy, surveillance often shifts to noninvasive fetal assessment with middle cerebral artery (MCA) Doppler ultrasound, which estimates fetal anemia by measuring blood flow velocity. Values at or above about 1.5 multiples of the median suggest moderate to severe anemia and may trigger further evaluation or intrauterine transfusion. Many guidelines also recommend additional antenatal testing, such as biophysical profiles or non‑stress tests in the third trimester, tailored to disease severity.  What treatments are available for fetuses and newborns affected by HDFN? For fetuses with moderate or severe anemia, intrauterine transfusion through the umbilical vein is a key therapy that can correct anemia and prevent hydrops or fetal death, often repeated at intervals until near term. After birth, management focuses on treating ongoing hemolysis and high bilirubin levels. Standard neonatal therapies include intensive phototherapy, exchange transfusions in severe cases, and in some settings intravenous immunoglobulin (IVIG) to reduce hemolysis. With timely diagnosis and access to these interventions, survival and long‑term neurodevelopmental outcomes have improved substantially in many regions.  How effective is Rh immune globulin (RhIG) in preventing RhD alloimmunization? Rh immune globulin is highly effective when given appropriately to RhD‑negative individuals who are pregnant or exposed to RhD‑positive red blood cells. A standard 300 microgram dose can prevent sensitization from approximately 15 mL of fetal red blood cells and, when administered routinely at around 28 weeks of gestation and again within 72 hours after delivery of an RhD‑positive infant, has reduced rates of RhD alloimmunization from more than 10% to well under 1–2% in many high‑income countries. RhIG is also recommended after sensitizing events such as miscarriage, trauma, or invasive procedures to maintain protection throughout pregnancy.  How common is HDFN worldwide, and why do rates differ between countries? Estimates suggest that in high‑income countries, HDFN affects roughly 3 to 80 per 100,000 live births, while in some low‑ and middle‑income settings reported rates range from about 252 to more than 500 per 100,000 live births. The much lower burden in wealthier countries is largely attributed to routine blood group screening, universal access to RhIG prophylaxis, and availability of specialized fetal therapy and neonatal intensive care. In contrast, limited access to prenatal care, delayed diagnosis, and shortages of RhIG and safe transfusion services contribute to higher prevalence and mortality in resource‑constrained regions.  What are some common misconceptions about blood type incompatibility in pregnancy? One misconception is that only ABO blood type differences matter in pregnancy, when in fact many red blood cell antigens beyond ABO can cause serious alloimmunization and HDFN. Another is that once RhIG is available, RhD problems are essentially “solved,” yet anti‑D remains an important cause of severe HDFN where prophylaxis is incomplete or unavailable, and non‑RhD antibodies are an increasing proportion of cases. It is also sometimes assumed that a “negative” antibody screen early in pregnancy guarantees no later risk, but sensitization can occur after mid‑pregnancy events such as bleeding or procedures, which is why repeat testing and appropriate prophylaxis are emphasized in modern guidelines.